Skip to main
RANI
RANI logo

RANI Stock Forecast & Price Target

RANI Analyst Ratings

Based on 11 analyst ratings
Strong Buy
Strong Buy 73%
Buy 27%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rani Therapeutics Holdings Inc. is advancing its proprietary RaniPill capsule technology, which enables the oral delivery of a wide range of biologics, including antibodies and peptides, providing a less painful alternative to injections. The company has demonstrated promising preclinical results, with plans to proceed to Phase 1c trials for obesity treatment, indicating progress and potential in tapping into the lucrative multi-billion dollar obesity market. Additionally, Rani's strategic collaborations, such as with ProGen, enhance its capacity to develop various obesity programs, solidifying its position in a competitive landscape while leveraging its innovative delivery platform.

Bears say

Rani Therapeutics Holdings Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to competitive pressures and regulatory uncertainties. The presence of several companies developing long-acting injectable formulations could diminish the market share and competitive advantage of the RaniPill, while management turnover may disrupt clinical development timelines, further impacting investor confidence. Additionally, risks associated with negative clinical trial outcomes, potential delays in receiving FDA approvals, and weak market adoption of Rani's products compound the uncertainties surrounding the company's future financial performance.

RANI has been analyzed by 11 analysts, with a consensus rating of Strong Buy. 73% of analysts recommend a Strong Buy, 27% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rani Therapeutics Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rani Therapeutics Holdings (RANI) Forecast

Analysts have given RANI a Strong Buy based on their latest research and market trends.

According to 11 analysts, RANI has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rani Therapeutics Holdings (RANI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.